BIOMAT Database Logo BIOMAT Database Logo

Protection from herpes simplex virus type 1 lethal and latent infections by secreted recombinant glycoprotein B constitutively expressed in human cells with a BK virus episomal vector. 1990

R Manservigi, and M P Grossi, and R Gualandri, and P G Balboni, and A Marchini, and A Rotola, and P Rimessi, and D Di Luca, and E Cassai, and G Barbanti-Brodano
Institute of Microbiology, School of Medicine, University of Ferrara, Italy.

The herpes simplex virus type 1 (HSV-1) glycoprotein B (gB-1) gene, deleted of 639 nucleotides that encode the transmembrane anchor sequence and reconstructed with the extramembrane and intracytoplasmic domains, was cloned under control of the Rous sarcoma virus long terminal repeat in the episomal replicating vector pRP-RSV, which contains the origin of replication and early region of the human papovavirus BK as well as a cDNA for a mutant mouse dihydrofolate reductase that is resistant to methotrexate. gB-1 (0.15 to 0.25 pg per cell per 24 h) was constitutively secreted into the culture medium of pRP-RSV-gBs-transformed human 293 cells. Treatment of transformed cells with methotrexate at high concentrations (0.6 to 6 microM) increased gB-1 production 10- to 100-fold, because of an amplification of the episomal recombinant. Mice immunized with secreted gB-1 produced HSV-1- and HSV-2-neutralizing antibodies and were protected against HSV-1 lethal, latent, and recurrent infections. Constitutive expression of secreted gB-1 in human cells may establish a system to develop diagnostic material and a subunit vaccine for HSV infections.

UI MeSH Term Description Entries
D007114 Immunization Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow). Immunologic Stimulation,Immunostimulation,Sensitization, Immunologic,Variolation,Immunologic Sensitization,Immunological Stimulation,Sensitization, Immunological,Stimulation, Immunologic,Immunizations,Immunological Sensitization,Immunological Sensitizations,Immunological Stimulations,Sensitizations, Immunological,Stimulation, Immunological,Stimulations, Immunological,Variolations
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D009693 Nucleic Acid Hybridization Widely used technique which exploits the ability of complementary sequences in single-stranded DNAs or RNAs to pair with each other to form a double helix. Hybridization can take place between two complimentary DNA sequences, between a single-stranded DNA and a complementary RNA, or between two RNA sequences. The technique is used to detect and isolate specific sequences, measure homology, or define other characteristics of one or both strands. (Kendrew, Encyclopedia of Molecular Biology, 1994, p503) Genomic Hybridization,Acid Hybridization, Nucleic,Acid Hybridizations, Nucleic,Genomic Hybridizations,Hybridization, Genomic,Hybridization, Nucleic Acid,Hybridizations, Genomic,Hybridizations, Nucleic Acid,Nucleic Acid Hybridizations
D010957 Plasmids Extrachromosomal, usually CIRCULAR DNA molecules that are self-replicating and transferable from one organism to another. They are found in a variety of bacterial, archaeal, fungal, algal, and plant species. They are used in GENETIC ENGINEERING as CLONING VECTORS. Episomes,Episome,Plasmid
D011120 Polyomavirus A genus of potentially oncogenic viruses of the family POLYOMAVIRIDAE. These viruses are normally present in their natural hosts as latent infections. The virus is oncogenic in hosts different from the species of origin. Bovine polyomavirus,Murine polyomavirus,Hamster polyomavirus,Polyoma Virus,Polyoma Viruses,Bovine polyomaviruses,Hamster polyomaviruses,Murine polyomaviruses,Polyomaviruses,Virus, Polyoma,Viruses, Polyoma,polyomavirus, Hamster,polyomaviruses, Bovine,polyomaviruses, Murine
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D001739 BK Virus A species of POLYOMAVIRUS apparently infecting over 90% of children but not clearly associated with any clinical illness in childhood. The virus remains latent in the body throughout life and can be reactivated under certain circumstances. BK polyomavirus,Human Polyomavirus BK,Polyomavirus, BK,Polyomavirus hominis 1,Polyomavirus BK, Human
D005260 Female Females
D005814 Genes, Viral The functional hereditary units of VIRUSES. Viral Genes,Gene, Viral,Viral Gene
D005822 Genetic Vectors DNA molecules capable of autonomous replication within a host cell and into which other DNA sequences can be inserted and thus amplified. Many are derived from PLASMIDS; BACTERIOPHAGES; or VIRUSES. They are used for transporting foreign genes into recipient cells. Genetic vectors possess a functional replicator site and contain GENETIC MARKERS to facilitate their selective recognition. Cloning Vectors,Shuttle Vectors,Vectors, Genetic,Cloning Vector,Genetic Vector,Shuttle Vector,Vector, Cloning,Vector, Genetic,Vector, Shuttle,Vectors, Cloning,Vectors, Shuttle

Related Publications

R Manservigi, and M P Grossi, and R Gualandri, and P G Balboni, and A Marchini, and A Rotola, and P Rimessi, and D Di Luca, and E Cassai, and G Barbanti-Brodano
Herpes simplex virus type 1-vaccinia virus recombinant expressing glycoprotein B: protection from acute and latent infection.
December 1988, The Journal of infectious diseases,
R Manservigi, and M P Grossi, and R Gualandri, and P G Balboni, and A Marchini, and A Rotola, and P Rimessi, and D Di Luca, and E Cassai, and G Barbanti-Brodano
Expression of herpes simplex virus 1 glycoprotein B by a recombinant vaccinia virus and protection of mice against lethal herpes simplex virus 1 infection.
August 1987, Proceedings of the National Academy of Sciences of the United States of America,
R Manservigi, and M P Grossi, and R Gualandri, and P G Balboni, and A Marchini, and A Rotola, and P Rimessi, and D Di Luca, and E Cassai, and G Barbanti-Brodano
Constitutive expression in human cells of herpes simplex virus type 1 glycoprotein B gene cloned in an episomal eukaryotic vector.
November 1988, Virology,
R Manservigi, and M P Grossi, and R Gualandri, and P G Balboni, and A Marchini, and A Rotola, and P Rimessi, and D Di Luca, and E Cassai, and G Barbanti-Brodano
Expression of herpes simplex virus 1 glycoprotein B in human cells and protection of mice against lethal herpes simplex virus 1 infection.
January 1989, Advances in experimental medicine and biology,
R Manservigi, and M P Grossi, and R Gualandri, and P G Balboni, and A Marchini, and A Rotola, and P Rimessi, and D Di Luca, and E Cassai, and G Barbanti-Brodano
Protection from lethal herpes simplex virus type 1 infection by vaccination with a UL41-deficient recombinant strain.
June 2016, Fukushima journal of medical science,
R Manservigi, and M P Grossi, and R Gualandri, and P G Balboni, and A Marchini, and A Rotola, and P Rimessi, and D Di Luca, and E Cassai, and G Barbanti-Brodano
Latent multiple infections by herpes simplex virus type 1.
January 1996, The Kurume medical journal,
R Manservigi, and M P Grossi, and R Gualandri, and P G Balboni, and A Marchini, and A Rotola, and P Rimessi, and D Di Luca, and E Cassai, and G Barbanti-Brodano
Latent multiple infections by herpes simplex virus type 1.
January 2000, The Kurume medical journal,
R Manservigi, and M P Grossi, and R Gualandri, and P G Balboni, and A Marchini, and A Rotola, and P Rimessi, and D Di Luca, and E Cassai, and G Barbanti-Brodano
Vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D prevents latent herpes in mice.
May 1985, Science (New York, N.Y.),
R Manservigi, and M P Grossi, and R Gualandri, and P G Balboni, and A Marchini, and A Rotola, and P Rimessi, and D Di Luca, and E Cassai, and G Barbanti-Brodano
Baculovirus expressed herpes simplex virus type 1 glycoprotein C protects mice from lethal HSV-1 infection.
June 1992, Antiviral research,
R Manservigi, and M P Grossi, and R Gualandri, and P G Balboni, and A Marchini, and A Rotola, and P Rimessi, and D Di Luca, and E Cassai, and G Barbanti-Brodano
Protection of mice against lethal challenge with herpes simplex virus by vaccination with an adenovirus vector expressing HSV glycoprotein B.
March 1989, Virology,
Copied contents to your clipboard!